MarketWatch

Wegovy(R) (semaglutide injection) Receives Conditional Marketing Authorization from Health Canada as the First and Only Treatment for Adults with Non-Cirrhotic MASH, a Serious ...

The MarketWatch News Department was not involved in the creation of this content. -- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment of non-cirrhotic ...
WebMD

FDA Approves Wegovy as First Once-Weekly Injection for Obesity-Linked Liver Disease

Wegovy (semaglutide) is a once-weekly injection that was first approved in 2017 to help with weight loss and lower the risk of heart problems. Now, the FDA has approved it to treat a liver condition ...
WebMD

MASH Clinical Trials

What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...
The American Journal of Managed Care

MASH Clinical Trials Historically Underrepresent Certain Groups

Racial and ethnic minorities are underrepresented in MASH RCTs, affecting the applicability of trial results to diverse populations. MASH is influenced by genetic, environmental, and social factors, ...